JP2000507917A
(ja)
|
1995-11-02 |
2000-06-27 |
シェーリング コーポレイション |
持続的低用量サイトカイン注入治療
|
US5908621A
(en)
|
1995-11-02 |
1999-06-01 |
Schering Corporation |
Polyethylene glycol modified interferon therapy
|
US20030190307A1
(en)
*
|
1996-12-24 |
2003-10-09 |
Biogen, Inc. |
Stable liquid interferon formulations
|
ATE375363T1
(de)
*
|
1997-07-14 |
2007-10-15 |
Bolder Biotechnology Inc |
Derivate des wachstumshormons und verwandte proteine
|
US7270809B2
(en)
*
|
1997-07-14 |
2007-09-18 |
Bolder Biotechnology, Inc. |
Cysteine variants of alpha interferon-2
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
TR200000728T2
(tr)
*
|
1997-09-18 |
2000-09-21 |
F.Hoffmann-La Roche Ag |
Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
|
US6172046B1
(en)
*
|
1997-09-21 |
2001-01-09 |
Schering Corporation |
Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
|
HU228877B1
(en)
*
|
1998-03-26 |
2013-06-28 |
Merck Sharp & Dohme |
Formulations for stabilization of peg-interferon alpha conjugates and method for preparation such formulations
|
US6180096B1
(en)
|
1998-03-26 |
2001-01-30 |
Schering Corporation |
Formulations for protection of peg-interferon alpha conjugates
|
TWI277424B
(en)
*
|
1998-05-15 |
2007-04-01 |
Schering Corp |
Combination therapy for eradicating detectable NCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
|
ITMI981148A1
(it)
*
|
1998-05-22 |
1999-11-22 |
Therapicon Srl |
Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
|
AU767131B2
(en)
*
|
1998-06-08 |
2003-10-30 |
F. Hoffmann-La Roche Ag |
Use of PEG-IFN-alpha and ribavirin for the treatment of chronic hepatitis C
|
EP1113794A2
(en)
*
|
1998-09-14 |
2001-07-11 |
Vertex Pharmaceuticals Incorporated |
Methods of treating viral disease
|
EP1656952B1
(en)
|
1998-10-16 |
2013-12-18 |
Biogen Idec MA Inc. |
Polyalkylene glycol conjugates of interferon beta-1A and uses thereof
|
PL200586B1
(pl)
|
1998-10-16 |
2009-01-30 |
Biogen Idec Inc |
Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów
|
EP1140143A2
(en)
*
|
1998-12-18 |
2001-10-10 |
Schering Corporation |
Ribavirin-pegylated interferon alfa induction hcv combination therapy
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
WO2000051631A2
(en)
*
|
1999-03-02 |
2000-09-08 |
Schering Corporation |
Pegylated alpha interferon for hiv therapy
|
US6362162B1
(en)
|
1999-04-08 |
2002-03-26 |
Schering Corporation |
CML Therapy
|
PT1043025E
(pt)
*
|
1999-04-08 |
2005-09-30 |
Schering Corp |
Tratamento de carcinoma da celula renal
|
US6923966B2
(en)
|
1999-04-08 |
2005-08-02 |
Schering Corporation |
Melanoma therapy
|
US6605273B2
(en)
|
1999-04-08 |
2003-08-12 |
Schering Corporation |
Renal cell carcinoma treatment
|
BR0009642A
(pt)
*
|
1999-04-08 |
2002-01-08 |
Schering Corp |
Terapia de leucemia mielocìtica crÈnica
|
PE20010027A1
(es)
*
|
1999-04-08 |
2001-02-05 |
Schering Corp |
Uso de interferon alfa pegilado en pacientes con melanoma
|
US6635646B1
(en)
*
|
1999-05-04 |
2003-10-21 |
Schering Corporation |
Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
|
CA2365900A1
(en)
*
|
1999-05-04 |
2000-11-09 |
Schering Corporation |
Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
|
RU2002105485A
(ru)
*
|
1999-08-13 |
2004-01-27 |
Ф.Хоффманн-Ля Рош Аг (Ch) |
Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α)
|
JP2003510281A
(ja)
*
|
1999-09-29 |
2003-03-18 |
ザ クリーブランド クリニック ファウンデーション |
2−5aおよびインターフェロンを用いる治療
|
JP2001288109A
(ja)
*
|
2000-04-06 |
2001-10-16 |
Schering Plough Corp |
黒色腫治療
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
KR20030036189A
(ko)
*
|
2000-05-26 |
2003-05-09 |
이데닉스(케이만)리미티드 |
플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
|
PT1311286E
(pt)
*
|
2000-08-07 |
2006-11-30 |
Sciclone Pharmaceuticals Inc |
Combinação farmacêutica que contém timosina e interferão pegilado para o tratamento do hepatite c
|
US7208167B2
(en)
*
|
2000-08-07 |
2007-04-24 |
Sciclone Pharmaceuticals, Inc. |
Treatment of hepatitis C with thymosin and peptide combination therapy
|
EP1324779B1
(en)
*
|
2000-09-29 |
2011-07-20 |
Schering Corporation |
Pegylated interleukin-10
|
US20020197235A1
(en)
*
|
2000-11-03 |
2002-12-26 |
Moran Stanford Mark |
Method for short-term and long-term drug dosimetry
|
US6878364B2
(en)
*
|
2000-12-01 |
2005-04-12 |
Cornell Research Foundation, Inc. |
Animal model for flaviviridae infection
|
US20020183271A1
(en)
*
|
2000-12-07 |
2002-12-05 |
Sunil Chada |
Methods of treatment involving human MDA-7
|
US6720000B2
(en)
|
2001-03-19 |
2004-04-13 |
Three Rivers Pharmaceutical, Llc |
Process for producing wet ribavirin pellets
|
WO2003026589A2
(en)
*
|
2001-09-28 |
2003-04-03 |
Idenix (Cayman) Limited |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
WO2003030923A1
(en)
*
|
2001-10-05 |
2003-04-17 |
Intermune, Inc. |
Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
|
UA78726C2
(en)
*
|
2001-11-01 |
2007-04-25 |
Sciclone Pharmaceuticals Inc |
Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
|
HUP0402364A2
(hu)
*
|
2001-11-02 |
2005-02-28 |
Sandoz Ag |
Gyorsan oldódó, nagy koncentrációjú ribavirinkészítmények
|
EP1536839B1
(en)
*
|
2001-11-09 |
2010-09-15 |
Intarcia Therapeutics, Inc |
Combination therapy comprising omega-interferon for treating infection with hepatitis c virus or yellow fever virus
|
KR100480429B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
|
AU2002346686A1
(en)
*
|
2001-12-07 |
2003-06-23 |
Intermune, Inc. |
Compositions and method for treating hepatitis virus infection
|
EP1476181B1
(en)
|
2002-01-18 |
2016-03-23 |
Biogen MA Inc. |
Polyalkylene polymer compounds and uses thereof
|
MXPA04007876A
(es)
*
|
2002-02-14 |
2005-06-20 |
Pharmasset Ltd |
Analogos de nucleosido fluorado modificados.
|
CA2477780A1
(en)
*
|
2002-03-05 |
2003-09-18 |
Board Of Regents, The University Of Texas System |
Methods of enhancing immune induction involving mda-7
|
WO2003101199A1
(en)
*
|
2002-05-31 |
2003-12-11 |
Schering Corporation |
Combination therapy for rna virus infections involving ribavirin and impdh inhibitors
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
DE14169110T1
(de)
|
2002-06-28 |
2022-05-12 |
Centre National De La Recherche Scientifique -Cnrs- |
Modifizierte 2'- und 3'-Nukleosid-Prodrugs zur Behandlung von Flaviridae-Infektionen
|
AU2003248748A1
(en)
*
|
2002-06-28 |
2004-01-19 |
Idenix (Cayman) Limited |
2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
CN101172993A
(zh)
*
|
2002-06-28 |
2008-05-07 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2′-c-甲基-3′-o-l-缬氨酸酯核糖呋喃基胞苷
|
AU2003256125A1
(en)
|
2002-08-31 |
2004-03-19 |
Cj Corp. |
Glycosylated human interferon alpha isoform
|
US7538094B2
(en)
*
|
2002-09-19 |
2009-05-26 |
Three Rivers Pharmacueticals, Llc |
Composition containing ribavirin and use thereof
|
AU2003295395A1
(en)
*
|
2002-11-04 |
2004-06-07 |
4Life Research, Lc |
Compositions, systems, and methods for focusing a cell-mediated immune response
|
KR20050088079A
(ko)
|
2002-11-15 |
2005-09-01 |
이데닉스 (케이만) 리미티드 |
2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
|
CN1738797A
(zh)
|
2002-11-19 |
2006-02-22 |
阿基里昂药品公司 |
取代的芳基硫脲和相关的化合物,病毒复制的抑制剂
|
CN100501400C
(zh)
|
2002-11-25 |
2009-06-17 |
希克龙制药公司 |
使用α胸腺素防护辐射损伤的方法
|
EP2319853B1
(en)
*
|
2002-12-12 |
2014-03-12 |
IDENIX Pharmaceuticals, Inc. |
Process for the production of 2'-branched nucleosides
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
GB0301879D0
(en)
*
|
2003-01-27 |
2003-02-26 |
Regent Res Llp |
HCV combination therapy
|
AU2003225670A1
(en)
*
|
2003-02-28 |
2004-09-28 |
Intermune, Inc. |
Interferon drug therapy for the treatment of viral diseases and liver fibrosis
|
WO2004078127A2
(en)
*
|
2003-02-28 |
2004-09-16 |
Intermune, Inc. |
Continuous delivery methods for treating hepatitis virus infection
|
AU2004218407A1
(en)
*
|
2003-03-03 |
2004-09-16 |
Board Of Regents, The University Of Texas System |
Methods and compositions involving MDA-7
|
US20070154454A1
(en)
*
|
2003-03-28 |
2007-07-05 |
Brian Murphy |
Compositions and methods for treating poxvirus infection
|
US20100311656A1
(en)
*
|
2003-04-23 |
2010-12-09 |
Sciclone Pharmaceuticals, Inc. |
Treatment or prevention of respiratory viral infections with alpha thymosin peptides
|
US7429572B2
(en)
|
2003-05-30 |
2008-09-30 |
Pharmasset, Inc. |
Modified fluorinated nucleoside analogues
|
GB0320638D0
(en)
*
|
2003-09-03 |
2003-10-01 |
Novartis Ag |
Organic compounds
|
CN103145715B
(zh)
|
2003-10-14 |
2016-08-03 |
F·霍夫曼-罗须公司 |
作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
|
CA2548220A1
(en)
*
|
2003-12-01 |
2005-09-09 |
Introgen Therapeutics, Inc. |
Use of mda-7 to inhibit infection by pathogenic organisms
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
JP2007519422A
(ja)
|
2004-02-02 |
2007-07-19 |
アンブレツクス・インコーポレイテツド |
修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
|
AU2008201682B2
(en)
*
|
2004-02-02 |
2011-02-24 |
Ambrx, Inc. |
Modified human interferon polypeptides and their uses
|
CN100355784C
(zh)
*
|
2004-02-12 |
2007-12-19 |
江苏恒瑞医药股份有限公司 |
聚乙二醇修饰α-干扰素1b的制备方法
|
US20070281041A1
(en)
*
|
2004-03-02 |
2007-12-06 |
Introgen Therapeutics, Inc. |
Compositions and Methods Involving MDA-7 for the Treatment of Cancer
|
US7754718B2
(en)
|
2004-05-05 |
2010-07-13 |
Yale University |
Antiviral helioxanthin analogs
|
SG169362A1
(en)
*
|
2004-05-14 |
2011-03-30 |
Sciclone Pharmaceuticals Inc |
Treatment or prevention of respiratory viral infections with immunomodulator compounds
|
EP1778272B1
(en)
*
|
2004-07-14 |
2011-02-09 |
Novartis AG |
Use of a combination of cyclosporin and pegylated interferons for treating hepatitis c (hcv)
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
JP4971160B2
(ja)
|
2004-08-12 |
2012-07-11 |
シェーリング コーポレイション |
安定するpeg化インターフェロン処方物
|
WO2006031725A2
(en)
|
2004-09-14 |
2006-03-23 |
Pharmasset, Inc. |
Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
US7892827B2
(en)
|
2004-11-26 |
2011-02-22 |
Pieris Ag |
Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
|
MX2007007779A
(es)
*
|
2004-12-23 |
2007-08-14 |
Novartis Ag |
Composiciones para el tratamiento de infeccion de hepatitis c.
|
WO2006071618A1
(en)
*
|
2004-12-23 |
2006-07-06 |
Novartis Ag |
Compounds for flaviviridae treatment
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
AU2006211960A1
(en)
*
|
2005-02-08 |
2006-08-17 |
Board Of Regents, The University Of Texas System |
Compositions and methods involving MDA-7 for the treatment of cancer
|
ES2302402B1
(es)
*
|
2005-06-16 |
2009-05-08 |
Proyecto De Biomedicina Cima, S.L. |
Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
|
CN101242842A
(zh)
|
2005-06-17 |
2008-08-13 |
诺瓦提斯公司 |
Sanglifehrin在hcv中的用途
|
US7695710B2
(en)
*
|
2005-06-20 |
2010-04-13 |
Pepgen Corporation |
Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
|
WO2007002233A2
(en)
*
|
2005-06-20 |
2007-01-04 |
Pepgen Corporation |
Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
|
EP2305697A3
(en)
|
2005-07-25 |
2011-07-27 |
Intermune, Inc. |
Macrocyclic inhibitors of Hepatitis C virus replication
|
DE602006019323D1
(de)
|
2005-10-11 |
2011-02-10 |
Intermune Inc |
Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
|
US7781576B2
(en)
*
|
2005-12-23 |
2010-08-24 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
EP1985303B1
(en)
|
2006-01-12 |
2012-11-21 |
Kitasato Daiichi Sankyo Vaccine Co., Ltd. |
Oral composition containing Interferon-alpha
|
US20070231301A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Warren Stephen L |
Parenteral low dose type 1 interferons for bladder cancer
|
JP5167244B2
(ja)
|
2006-04-11 |
2013-03-21 |
ノバルティス アーゲー |
Hcv/hiv阻害剤およびそれらの使用
|
DE602007009377D1
(de)
|
2006-05-30 |
2010-11-04 |
Intarcia Therapeutics Inc |
Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
|
US8114150B2
(en)
*
|
2006-06-14 |
2012-02-14 |
Advanced Cardiovascular Systems, Inc. |
RGD peptide attached to bioabsorbable stents
|
AR078117A1
(es)
|
2006-06-20 |
2011-10-19 |
Protech Pharma S A |
Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
|
WO2008088581A2
(en)
*
|
2006-08-02 |
2008-07-24 |
United Therapeutics Corporation |
Liposome treatment of viral infections
|
US7682356B2
(en)
|
2006-08-09 |
2010-03-23 |
Intarcia Therapeutics, Inc. |
Osmotic delivery systems and piston assemblies for use therein
|
WO2008063727A2
(en)
*
|
2006-08-21 |
2008-05-29 |
United Therapeutics Corporation |
Combination therapy for treatment of viral infections
|
US8679472B1
(en)
|
2006-10-05 |
2014-03-25 |
Merck, Sharp & Dohme Corp. |
Crystal of human interferon alpha 2B in complex with zinc
|
KR20090083902A
(ko)
*
|
2006-10-12 |
2009-08-04 |
노파르티스 아게 |
개질된 사이클로스포린의 용도
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
JP5351884B2
(ja)
|
2007-04-23 |
2013-11-27 |
インターシア セラピューティクス,インコーポレイティド |
インスリン分泌促進性ペプチドの懸濁製剤及び使用
|
CA2685596A1
(en)
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
SG188143A1
(en)
|
2008-02-08 |
2013-03-28 |
Ambrx Inc |
Modified leptin polypeptides and their uses
|
CA2726861C
(en)
|
2008-02-13 |
2014-05-27 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
WO2009118658A2
(en)
*
|
2008-03-26 |
2009-10-01 |
University Of Oxford |
Endoplasmic reticulum targeting liposomes
|
TW200946541A
(en)
*
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
JP6112766B2
(ja)
|
2008-04-29 |
2017-04-12 |
アセンディス ファーマ グロウス ディスオーダーズ ディヴィジョン エー/エス |
Peg化された組換えヒト成長ホルモン化合物
|
EP2113256A1
(en)
|
2008-04-29 |
2009-11-04 |
Ascendis Pharma AS |
PEGylated rhGH compounds
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
EP2313430B1
(en)
|
2008-06-24 |
2018-05-02 |
Technische Universität München |
Muteins of hngal and related proteins with affinity for a given target
|
BRPI0918653A2
(pt)
*
|
2008-09-17 |
2015-12-01 |
Boehringer Ingelheim Int |
combinação de inibidor de ns3 protese de hcv com interferon e ribavirina.
|
US8691205B2
(en)
|
2008-12-17 |
2014-04-08 |
Merck Sharp & Dohme Corporation |
Mono- and di-PEG IL-10 production; and uses
|
EP2376088B1
(en)
|
2008-12-23 |
2017-02-22 |
Gilead Pharmasset LLC |
6-O-Substituted-2-amino-purine nucleoside phosphoramidates
|
US8551973B2
(en)
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
EA019295B1
(ru)
|
2008-12-23 |
2014-02-28 |
Джилид Фармассет, Ллс. |
Соединения пуриновых нуклеозидов и способ их получения
|
JP2012521981A
(ja)
*
|
2009-03-27 |
2012-09-20 |
ザ チャンセラー,マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード |
コレステロールレベル低下リポソーム
|
JP5576928B2
(ja)
*
|
2009-03-27 |
2014-08-20 |
ジェイダブリュ ファーマシューティカル コーポレーション |
インターフェロン−アルファ及び細胞質残留性細胞膜透過ペプチドを含むIFN−α融合タンパク質
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
WO2011014882A1
(en)
|
2009-07-31 |
2011-02-03 |
Medtronic, Inc. |
CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
|
WO2011015634A2
(en)
|
2009-08-05 |
2011-02-10 |
Pieris Ag |
Controlled release formulations of lipocalin muteins
|
HUE035862T2
(en)
|
2009-09-28 |
2018-05-28 |
Intarcia Therapeutics Inc |
Rapid development and / or completion of substantially steady-state drug delivery
|
EA201200650A1
(ru)
|
2009-10-30 |
2012-12-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
|
BR112012013662B1
(pt)
|
2009-12-07 |
2022-08-02 |
Pieris Pharmaceuticals Gmbh |
Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
JP2013527145A
(ja)
|
2010-03-31 |
2013-06-27 |
ギリード・ファーマセット・エルエルシー |
リン含有活性化剤の立体選択的合成
|
NZ603562A
(en)
|
2010-06-08 |
2014-07-25 |
Pieris Ag |
Tear lipocalin muteins binding il-4 r alpha
|
WO2011159930A2
(en)
|
2010-06-16 |
2011-12-22 |
Medtronic, Inc. |
Damping systems for stabilizing medications in drug delivery devices
|
EP2585065A1
(en)
|
2010-06-24 |
2013-05-01 |
Panmed Ltd. |
Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
|
DK2606061T3
(da)
|
2010-08-16 |
2017-11-06 |
Pieris Pharmaceuticals Gmbh |
Bindingsproteiner til hepcidin
|
WO2012045704A1
(en)
|
2010-10-05 |
2012-04-12 |
Novartis Ag |
New treatments of hepatitis c virus infection
|
EP2624826B1
(en)
|
2010-10-08 |
2018-07-18 |
Novartis AG |
Vitamin e formulations of sulfamide ns3 inhibitors
|
EP2640740B1
(en)
|
2010-11-15 |
2017-03-15 |
Pieris Pharmaceuticals GmbH |
Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
|
AR084044A1
(es)
|
2010-11-30 |
2013-04-17 |
Pharmasset Inc |
Compuestos 2’-espiro-nucleosidos
|
JP6110791B2
(ja)
|
2010-11-30 |
2017-04-05 |
ノバルティス アーゲー |
C型肝炎ウイルス感染症の新規治療
|
EP2646552B1
(en)
|
2010-12-02 |
2017-07-05 |
Pieris Pharmaceuticals GmbH |
Muteins of human lipocalin 2 with affinity for ctla-4
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
EP2691094A1
(en)
|
2011-03-31 |
2014-02-05 |
Novartis AG |
Alisporivir to treat hepatitis c virus infection
|
RU2013148779A
(ru)
|
2011-04-01 |
2015-05-10 |
Новартис Аг |
Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
|
AU2012241859A1
(en)
|
2011-04-13 |
2013-10-10 |
Debiopharm International Sa |
Treatment of Hepatitis C virus infection with alisporivir
|
WO2013045460A1
(en)
|
2011-09-27 |
2013-04-04 |
Novartis Ag |
Alisporivr for treatment of hepatis c virus infection
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
HUE042720T2
(hu)
|
2011-12-13 |
2019-07-29 |
Pieris Pharmaceuticals Gmbh |
Eljárás bizonyos rendellenességek megelõzésére vagy kezelésére IL-4 és/vagy IL-13 saját receptorához történõ kötõdésének gátlása révén
|
US8809354B2
(en)
|
2011-12-31 |
2014-08-19 |
Sheikh Riazuddin |
3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
|
WO2013137869A1
(en)
|
2012-03-14 |
2013-09-19 |
Boehringer Ingelheim International Gmbh |
Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
|
JP2015512900A
(ja)
|
2012-03-28 |
2015-04-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
特別な患者の遺伝子亜型分集団のhcv感染症を治療するための併用療法
|
WO2013174783A1
(en)
|
2012-05-23 |
2013-11-28 |
Pieris Ag |
Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
|
AU2014230460B2
(en)
|
2013-03-14 |
2018-04-05 |
Pieris Pharmaceuticals Gmbh |
Novel binding proteins for PCSK9
|
CA2891557A1
(en)
|
2013-03-26 |
2014-05-22 |
Pieris Ag |
Novel specific-binding polypeptides and uses thereof
|
US9943568B2
(en)
|
2013-04-18 |
2018-04-17 |
Armo Biosciences, Inc. |
Methods of using pegylated interleukin-10 for treating cancer
|
ES2688206T3
(es)
|
2013-06-17 |
2018-10-31 |
Armo Biosciences, Inc. |
Procedimiento de evaluación de la identidad y la estabilidad de proteínas
|
PL3650014T3
(pl)
|
2013-08-27 |
2022-01-31 |
Gilead Pharmasset Llc |
Preparat złożony dwóch związków przeciwwirusowych
|
CN105658232A
(zh)
|
2013-08-30 |
2016-06-08 |
阿尔莫生物科技股份有限公司 |
使用白细胞介素-10治疗疾病和病症的方法
|
WO2015070060A1
(en)
|
2013-11-11 |
2015-05-14 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
AU2015205530B8
(en)
|
2014-01-13 |
2019-09-19 |
Pieris Pharmaceuticals Gmbh |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
DK3145945T3
(da)
|
2014-05-22 |
2020-09-28 |
Pieris Pharmaceuticals Gmbh |
Hidtil ukendte specifikt bindende polypeptider og anvendelser deraf
|
US10293043B2
(en)
|
2014-06-02 |
2019-05-21 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
MX2017004838A
(es)
|
2014-10-14 |
2017-10-16 |
Armo Biosciences Inc |
Composiciones de interleucina-15 y usos de estas.
|
AU2015336101A1
(en)
|
2014-10-22 |
2017-04-20 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
HRP20211734T8
(hr)
|
2014-11-21 |
2022-03-04 |
Ascendis Pharma Endocrinology Division A/S |
Dozni oblici dugodjelujućeg hormona rasta
|
EP3250586B1
(en)
|
2015-01-28 |
2021-10-27 |
Pieris Pharmaceuticals GmbH |
Novel proteins specific for angiogenesis
|
US10618970B2
(en)
|
2015-02-03 |
2020-04-14 |
Armo Biosciences, Inc. |
Method of treating cancer with IL-10 and antibodies that induce ADCC
|
TW201636364A
(zh)
|
2015-02-18 |
2016-10-16 |
賽諾菲公司 |
對於螢光鐵載體及綠膿桿菌螯鐵蛋白具特異性之新穎蛋白
|
CN114316067A
(zh)
|
2015-05-04 |
2022-04-12 |
皮里斯制药有限公司 |
抗癌融合多肽
|
SG11201708339QA
(en)
|
2015-05-04 |
2017-11-29 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for cd137
|
RU2754466C2
(ru)
|
2015-05-18 |
2021-09-02 |
ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ |
Слитый полипептид с противораковой активностью
|
WO2016184875A1
(en)
|
2015-05-18 |
2016-11-24 |
Pieris Pharmaceuticals Gmbh |
Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
|
EP3302547A1
(en)
|
2015-05-28 |
2018-04-11 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
ES2968262T3
(es)
|
2015-06-03 |
2024-05-08 |
I2O Therapeutics Inc |
Sistemas de colocación de implantes
|
EP3115371A1
(en)
|
2015-07-07 |
2017-01-11 |
Sanofi |
Fusion molecules
|
MX2018000447A
(es)
|
2015-07-15 |
2018-08-15 |
Pieris Pharmaceuticals Gmbh |
Novedosas proteinas especificas para lag-3.
|
EP3341012A4
(en)
|
2015-08-25 |
2019-03-20 |
Armo Biosciences, Inc. |
METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
|
SG10201911499TA
(en)
|
2015-11-30 |
2020-01-30 |
Pieris Australia Pty Ltd |
Novel anti-angiogenic fusion polypeptides
|
TW201725212A
(zh)
|
2015-12-10 |
2017-07-16 |
第一三共股份有限公司 |
特異性於降鈣素基因相關胜肽的新穎蛋白
|
WO2017200943A1
(en)
|
2016-05-16 |
2017-11-23 |
Intarcia Therapeutics, Inc. |
Glucagon-receptor selective polypeptides and methods of use thereof
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
WO2017222940A1
(en)
*
|
2016-06-20 |
2017-12-28 |
Eli Lilly And Company |
Pegylated porcine interferon and methods of use thereof
|
WO2018035281A1
(en)
|
2016-08-17 |
2018-02-22 |
North Carolina State University |
Northern-southern route to synthesis of bacteriochlorins
|
WO2018087108A1
(en)
|
2016-11-09 |
2018-05-17 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for cd137
|
US10836774B2
(en)
|
2016-11-30 |
2020-11-17 |
North Carolina State University |
Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
|
CN110225762A
(zh)
|
2017-01-03 |
2019-09-10 |
因塔西亚制药公司 |
包括glp-1受体激动剂的连续施用和药物的共同施用的方法
|
CN110402252A
(zh)
|
2017-01-18 |
2019-11-01 |
皮里斯制药有限公司 |
对lag-3具有结合亲和力的脂质运载蛋白突变蛋白
|
KR20210040103A
(ko)
|
2018-07-31 |
2021-04-12 |
피어이스 파마슈티컬즈 게엠베하 |
Cd137 및 pd-l1에 특이적인 신규한 융합 단백질
|
CA3124441A1
(en)
|
2019-02-26 |
2020-09-03 |
Pieris Pharmaceuticals Gmbh |
Novel fusion proteins specific for cd137 and gpc3
|
EP4161957A1
(en)
|
2020-06-05 |
2023-04-12 |
Pieris Pharmaceuticals GmbH |
Multimeric immunomodulator targeting 4-1bb
|
KR20230165917A
(ko)
|
2021-04-08 |
2023-12-05 |
피어이스 파마슈티컬즈 게엠베하 |
결합 조직 성장 인자(ctgf)에 특이적인 신규 리포칼린 뮤테인
|
WO2022243341A1
(en)
|
2021-05-18 |
2022-11-24 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for ox40
|
WO2024064713A1
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Novel fusion protein specific for cd137 and cd228
|